BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Walter E, Hausberger S, Groß E, Siebert U. Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. Journal of Medical Economics 2020;23:1061-71. [DOI: 10.1080/13696998.2020.1801187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Langbrandtner J, Steimann G, Reichel C, Bokemeyer B, Hüppe A. [Inflammatory Bowel Disease - Challenges in the Workplace and Support for Coping with Disease]. Rehabilitation (Stuttg) 2021. [PMID: 34544161 DOI: 10.1055/a-1581-6497] [Reference Citation Analysis]
2 Allocati E, Godman B. Key patient related factors in the management of inflammatory bowel disease. J Med Econ 2020;23:1606-9. [PMID: 33210979 DOI: 10.1080/13696998.2020.1838913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Zhou T, Sheng Y, Guan H, Meng R, Wang Z. Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China. Front Public Health 2021;9:704889. [PMID: 34490187 DOI: 10.3389/fpubh.2021.704889] [Reference Citation Analysis]
4 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Reference Citation Analysis]